Results 181 to 190 of about 23,607 (294)

Sustainable Synthesis of 4,7‐Dihydro‐4,7‐ethano‐2H‐isoindoles—Key Building Blocks to Benzoporphyrins

open access: yesChemistry – A European Journal, EarlyView.
A facile and sustainable route to isoindole derivatives—key benzoporphyrin precursors—brings high‐ and low‐symmetry benzoporphyrins closer to practical application. ABSTRACT Benzoporphyrins, π extended porphyrin analogues, exhibit remarkable potential for optoelectronic and theragnostic applications, yet have remained largely confined to fundamental ...
Lampros Pascal Gazetas   +5 more
wiley   +1 more source

Total Syntheses of Agelamadin F and (±)‐Tauroacidin A, Enabled by NaClO2‐Mediated Coupling Reactions of Oroidin and Amines

open access: yesChemistry – A European Journal, EarlyView.
Total syntheses of agelamadin F and (±)‐tauroacidin A were achieved by sodium chlorite (NaClO2)‐mediated oxidative C─N coupling. Nine C15–N–amino acid‐substituted oroidin derivatives were successfully prepared to demonstrate the applicability and versatility of this oxidative coupling reaction.
Ryosuke Hirozumi   +3 more
wiley   +1 more source

Alkali‐Metal Base Catalyzed Electrocyclization of Isoprene Derivatives

open access: yesChemistry – A European Journal, EarlyView.
Simple and abundant alkali‐metal base catalysis in combination with Lewis basic polyamines enables the electrocyclization of isoprene‐derived trienes to cycloheptadienes under neat conditions. Mechanistic insight supported by DFT guides a scalable route to seven‐membered carbocycles which, after reduction, give saturated cycloalkanes relevant as ...
Mikaël Le Roch   +3 more
wiley   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland   +48 more
wiley   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary   +59 more
wiley   +1 more source

A Social Entrepreneurship Perspective of De‐Carbonising the Footprint through Recycling Compensation: A Case Study of the NGO Madre Coraje

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT This research analyses the carbon footprint of the NGO Madre Coraje, using an integrated methodology that combines the calculator provided by REAS (Red de Economía Alternativa y Solidaria) Navarra and the Life Cycle Assessment (LCA). It quantifies emissions across the three scopes of the Greenhouse Gas Protocol, evaluating both direct and ...
José Fernandez‐Serrano   +2 more
wiley   +1 more source

Artificial Intelligence as a Catalyst for Environmental and Social Sustainability Practices in SMEs: The Moderating Role of Sustainability, Digitalization, and Innovation Barriers

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT This study examines the relationship between artificial intelligence and both environmental and social sustainability practices in small and medium‐sized enterprises, with a specific focus on the moderating effects of implementation barriers relating to sustainability, digitalization, and innovation.
Gülçinay Mumcu, Steven A. Brieger
wiley   +1 more source

Home - About - Disclaimer - Privacy